COVID-19 and dermatology

Background/aim: Sars-CoV-2 virus infection (COVID-19) was observed in China in the last months of 2019. In the period following, this infection spread all over the world. In March 2020 the World Health Organization announced the existence of a pandemic. The aim of this manuscript is to investigate skin diseases associated with COVID-19 under three main headings: skin problems related to personal protective equipment and personal hygiene measures, skin findings observed in SARS-CoV-2 virus infections, and skin findings due to COVID-19 treatment agents. Materials and methods: In PubMed, Google Scholar databases, skin lesions related to personal protective equipment and personal hygiene measures, skin findings observed in SARS-CoV-2 virus infections and skin findings due to COVID-19 treatment agents subjects are searched in detail. Results: Pressure injury, contact dermatitis, itching, pressure urticaria, exacerbation of preexisting skin diseases, and new skin lesion occurrence/new skin disease occurrence may be due to personal protective equipment. Skin problems related to personal hygiene measures could include itching, dryness, and contact dermatitis. Skin findings may also be observed in SARS-CoV-2 virus infections. The incidence of skin lesions due to COVID-19 was reported to be between 0.2% and 29%. Many skin lesions including maculopapular, urticarial, vesicular, chilblain-like, thrombotic/ischemic, etc. are observed in COVID-19 patients. Some authors have stated that there is an absence of SARS-CoV-2 virus infection-specific skin findings. However, in asymptomatic or presymptomatic COVID-19 patients in particular, skin lesions can lead to the diagnosis of COVID-19. In addition, skin lesions may occur due to COVID-19 treatment agents. Conclusion: Many skin lesions may appear as a result of COVID-19. Even in the absence of a COVID-19 diagnosis, skin findings should be evaluated carefully in this pandemic period.

PDF

___

1. Hafeez A, Ahmad S, Siddqui SA, Ahmad M, Mishra S. A review of COVID-19 (Coronavirus Disease-2019) diagnosis, treatments and prevention. Eurasian Journal of Medicine and Oncology 2020; 4(2):116-125. doi:10.14744/ejmo.2020.90853
2. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio-medica: Atenei Parmensis 2020; 91(1):157-160. doi:10.23750/abm.v91i1.9397
3. Zhao N, Zhou ZL, Wu L, Zhang XD, Han SB et al. An update on the status of COVID-19: a comprehensive review. European Review for Medical and Pharmacological Sciences 2020; 24(8):4597-4606. doi:10.26355/eurrev_202004_21046
4. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). International Journal of Infectious Diseases 2020; 94: 154-155. doi:10.1016/j.ijid.2020.03.020
5. Hu Z, Song C, Xu C, Jin G, Chen Y et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Science China. Life Sciences 2020; 63 (5): 706-711. doi:10.1007/s11427-020-1661- 4
6. Dong X, Cao YY, Lu XX, Zhang JJ, Du H et al. Eleven faces of coronavirus disease 2019. Allergy 2020; 10.1111/all.14289. doi:10.1111/all.14289
7. Ai T, Yang Z, Hou H, Zhan C, Chen C et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020: 200642. doi:10.1148/radiol.2020200642
8. Galván Casas C, Català A, Carretero Hernández G, RodríguezJiménez P, Fernández Nieto D et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. British Journal of Dermatology 2020. doi:10.1111/bjd.19163
9. Zhang Z, Zhang L, Wang Y. COVID-19 indirect contact transmission through the oral mucosa must not be ignored. Journal of Oral Pathology & Medicine 2020; 49 (5): 450-451. doi:10.1111/jop.13019
10. Yan Y, Chen H, Chen L, Cheng B, Diao P et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019. Dermatologic Therapy 2020: e13310. doi:10.1111/ dth.13310
11. Kwatra SG, Sweren RJ, Grossberg AL. Dermatology practices as vectors for COVID-19 transmission: A call for immediate cessation of nonemergent dermatology visits. Journal of the American Academy of Dermatology 2020; 82 (5): e179-e180. doi:10.1016/j.jaad.2020.03.037
12. Gisondi P, Piaserico S, Conti A, Naldi L. Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. Journal of the European Academy of Dermatology and Venereology 2020. doi: 10.1111/jdv.16515
13. Wollina U. Challenges of COVID-19 pandemic for dermatology. Dermatologic Therapy 2020: e13430. doi:10.1111/dth.13430
14. Borgatta L, Fisher M, Robbins N. Hand protection and protection from hands: hand-washing, germicides and gloves. Women & Health 1989; 15(4): 77-92.
15. Pei S, Xue Y, Zhao S, Alexander N, Mohamad G et al. Occupational skin conditions on the frontline: A survey among 484 Chinese healthcare professionals caring for Covid-19 patients. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16570
16. Zuo Y, Hua W, Luo Y, Li L. Skin reactions of N95 masks and medial masks among health care personnel: A self-report questionnaire survey in China. Contact Dermatitis 2020. doi:10.1111/cod.13555
17. Foo CC, Goon AT, Leow YH, Goh CL. Adverse skin reactions to personal protective equipment against severe acute respiratory syndrome--a descriptive study in Singapore. Contact Dermatitis 2006; 55(5): 291-294.
18. Lin P, Zhu S, Huang Y, Li L, Tao J et al. Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: A survey in Wuhan and its surrounding regions. British Journal of Dermatology 2020. doi:10.1111/bjd.19089
19. Zhang B, Zhai R, Ma L. COVID-19 epidemic: Skin protection for health care workers must not be ignored. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16573
20. Lan J, Song Z, Miao X, Li H, Li Y et al. Skin damage among health care workers managing coronavirus disease-2019. Journal of the American Academy of Dermatology 2020; 82 (5): 1215-1216. doi:10.1016/j.jaad.2020.03.014
21. Darlenski R, MD, Tsankov N. Covid-19 pandemic and the skin - What should dermatologists know? Clinics in Dermatology 2020. doi:10.1016/j.clindermatol.2020.03.012
22. Oranges T, Janowska A, Dini V. Reply to: “Skin damage among health care workers managing coronavirus disease-2019”. The Journal of the American Academy of Dermatology 2020; 82 (6): e233–e234. doi:10.1016/j.jaad.2020.04.003
23. Jiang W, Cao W, Liu Q. Wearing the N95 mask with a plastic handle reduces pressure injury. Journal of the American Academy of Dermatology 2020; 82: e191-192. pii: S0190- 9622(20)30532-6. doi:10.1016/j.jaad.2020.04.001
24. Payne A. Covid-19: skin damage with prolonged wear of FFP3 masks. British Medical Journal 2020; 369:m1743. doi:10.1136/ bmj.m1743
25. Gheisari M, Araghi F, Moravvej H, Tabary M, Dadkhahfar S. Skin reactions to non-glove personal protective equipment: An emerging issue in the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16492
26. Balato A, Ayala F, Bruze M, Crepy MN, Gonçalo M, Duus Johansen J et al. European task force on contact dermatitis statement on coronavirus 19 disease (COVID-19) outbreak and the risk of adverse cutaneous reactions. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16557
27. Donovan J, Kudla I, Holness L, Skotnicki-Grant S, Nethercott J. Skin reactions following use of N95 facial masks. Dermatitis 2007; 18: 104.
28. Donovan J, Skotnicki-Grant S. Allergic contact dermatitis from formaldehyde textile resins in surgical uniforms and nonwoven textile masks. Dermatitis 2006; 18 (1): 40-44.
29. Gheisari M, Araghi F, Moravvej H, Tabary M, Dadkhahfar S. Skin reactions to non-glove personal protective equipment: An emerging ıssue in the COVID-19 Pandemic. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16492
30. Abtahi-Naeini B. Frequent handwashing amidst the COVID-19 outbreak: prevention of hand irritant contact dermatitis and other considerations. Health Science Reports 2020; 3(2):e163. doi:10.1002/hsr2.163
31. Guan W, Ni Z, Hu Y, Liang W, Ou C et al. Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine 2020. doi:10.1056/NEJMoa2002032
32. Alramthan A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East. Clinical and Experimental Dermatology 2020. doi:10.1111/ced.14243
33. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson Regnault M. Comment on “Cutaneous manifestations in COVID-19: a first perspective “ by Recalcati S. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16519
34. Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with Coronavirus Disease 2019? Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16471
35. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16387
36. Estébanez A, Pérez-Santiago L, Silva E, Guillen-Climent S, García-Vázquez A, Ramón M. Cutaneous manifestations in COVID-19: a new contribution. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/ jdv.16474
37. Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, Suarez-Valle A, Moreno-Arrones OM, Saceda-Corralo D et al. Characterization of acute acro-ischemic lesions in nonhospitalized patients: a case series of 132 patients during the COVID-19 outbreak. Journal of the American Academy of Dermatology 2020. doi:10.1016/j.jaad.2020.04.093
38. Mungmungpuntipantip R, Wiwanitkit V. COVID-19 and cutaneous manifestations. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16483
39. Sachdeva M, Gianotti R, Shah M, Lucia B, Tosi T et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. Journal of Dermatological Science 2020. doi:10.1016/j.jdermsci.2020.04.011
40. Morey-Olivé M, Espiau M, Mercadal-Hally M, Lera-Carballo E, García-Patos V. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019). Anales de Pediatría (English Edition) 2020. doi:10.1016/j. anpede.2020.04.002
41. Gianotti R, Veraldi S, Recalcati S, Cusini M, Ghislanzoni M et al. Cutaneous clinico-pathological findings in three COVID-19-positive patients observed in the metropolitan area of Milan, Italy. Acta Dermato-Venereologica 2020. doi:10.2340/00015555-3490
42. Bouaziz JD, Duong T, Jachiet M, Velter C, Lestang P et al. Vascular skin symptoms in COVID-19: a french observational study. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16544
43. Chesser H, Chambliss JM, Zwemer E. Acute hemorrhagic edema of ınfancy after 39 coronavirus ınfection with recurrent rash. Case Reports in Pediatrics 2017; 2017: 5637503.
44. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for Dengue. Journal of the American Academy of Dermatology 2020. pii: S0190-9622(20)30454-0. doi:10.1016/j. jaad.2020.03.036
45. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020 . doi:10.1111/all.14238
46. Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16472
47. van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16523
48. Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. American Journal of Clinical Dermatology 2020. doi:10.1007/s40257-020-00514-2
49. Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16530
50. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19 pandemic. International Journal of Dermatology 2020. doi:10.1111/ijd.14937
51. Andina D, Noguera-Morel L, Bascuas-Arribas M, GaiteroTristán J, Alonso-Cadenas JA et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatric Dermatology 2020. doi:10.1111/pde.14215
52. López-Robles J, de la Hera I, Pardo J, Martínez J, Cutillas-Marco E. Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic. Clinical and Experimental Dermatology 2020. doi:10.1111/ced.14275
53. Recalcati S, Barbagallo T, Frasin LA, Prestinari F, Cogliardi A et al. Acral cutaneous lesions in the Time of COVID-19. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16533
54. Torres-Navarro I, Abril-Pérez C, Roca-Ginés J, Sánchez-Arráez J, Botella-Estrada R, Évole-Buselli M. Comment on ‘Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East’: pernio unrelated to COVID-19. Clinical and Experimental Dermatology 2020. doi:10.1111/ced.14255
55. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/ jdv.16526
56. Kolivras A, Dehavay F, Delplace D, Feoli F, Meiers I et al. Coronavirus (COVID-19) infection induced chilblains: a case report with histopathological findings. Journal of the American Academy of Dermatology Case Reports 2020. doi:10.1016/j. jdcr.2020.04.011
57. Zhang Y, Cao W, Xiao M, Li YJ, Yang Y et al. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi 2020; 41(0):E006. doi:10.3760/cma.j.issn.0253-2727.2020.0006
58. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerging Microbes & Infections 2020; 9 (1): 687-690. doi:10.1080/22221751.2020.1741327
59. Zhang Y, Xiao M, Zhang S, Xia P, Cao W et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. New England Journal of Medicine 2020; 382 (17): e38. doi:10.1056/ NEJMc2007575
60. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 2020; 18(4): 844-847.
61. Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, Suarez-Valle A, Saceda-Corralo D et al. Erythema multiformelike eruption in patients with COVID-19 infection: clinical and histological findings. Clinical and Experimental Dermatology 2020. doi:10.1111/ced.14281
62. Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti A et al. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16613
63. Janah H, Zinebi A, Elbenaye J. Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16623
64. Castelnovo L, Capelli F, Tamburello A, Maria Faggioli P, Mazzone A. Symmetric cutaneous vasculitis in COVID-19 pneumonia. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16589
65. Manalo IF, Smith MK, Cheeley J, Jacobs R. A Dermatologic manifestation of COVID-19: transient livedo reticularis. Journal of the American Academy of Dermatology 2020. doi:10.1016/j.jaad.2020.04.018
66. Amatore F, Macagno N, Mailhe M, Demarez B, GaudyMarqueste C et al. SARS-CoV-2 infection presenting as a febrile rash. Journal of the European Academy of Dermatology and Venereology 2020. doi:10.1111/jdv.16528
67. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 2020. doi:10.1111/jth.14830
68. Carreras-Presas CM, Sánchez JA, López-Sánchez AF, JanéSalas E, Somacarrera Pérez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Diseases 2020. doi:10.1111/odi.13382
69. Gonzalez CD, Hansen C, Clarke JT. Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study. Journal of the American Academy of Dermatology 2019; 81(3): 859-860. doi:10.1016/j.jaad.2019.04.068
70. Schwartz RA, Janniger CK. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Dermatologic Therapy 2020: e13380. doi:10.1111/dth.13380
71. Gül Ü, Cakmak SK, Kiliç A, Gonul M, Bilgili S. A case of hydroxychloroquine induced pruritus. European Journal of Dermatology 2006; 16(5): 586-587.
72. Salido M, Joven B, D’Cruz DP, Khamashta MA, Hughes GR. Increased cutaneous reactions to hydroxychloroquine (Plaquenil) possibly associated with formulation change: comment on the letter by Alarcón. Arthritis & Rheumatology 2002; 46(12): 3392-3396.
73. Das A, Sancheti K, Podder I, Das NK. Azithromycin induced bullous fixed drug eruption. Indian Journal of Pharmacology 2016; 48 (1): 83-85. doi:10.4103/0253-7613.174565
74. Sriratanaviriyakul N, Nguyen LP, Henderson MC, Albertson TE. Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock: a case report. Journal of Medical Case Reports 2014; 8: 332. doi:10.1186/1752-1947-8-332
75. Aihara Y, Ito S, Kobayashi Y, Aihara M. Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection. Allergy. 2004; 59(1): 118.
76. Cascaval RI, Lancaster DJ. Hypersensitivity syndrome associated with azithromycin. American Journal of Medicine 2001; 110(4): 330-331. doi:10.1016/S0002-9343(00)00724-5
77. Odemis E, Kalyoncu M, Okten A, Yildiz K. Azithromycin-induced leukocytoclastic vasculitis. Journal of Rheumatology 2003; 30(10): 2292.
78. Cai Q, Yang M, Liu D, Chen J, Shu D et al.Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing). 2020. doi:10.1016/j.eng.2020.03.007
79. Wang Y, Zhang D, Du G, Du R, Zhao J et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial. Lancet 2020. doi:10.1016/S0140- 6736(20)31022-9
80. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E et al. Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine 2020. doi:10.1056/ NEJMoa2007016
81. Nordstrom BL, Oh K, Sacks ST, L’Italien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. Antiviral Therapy 2004; 9(2): 187-195.
82. Kalsi T, Stevenson J, Wade P, Kinirons M. Tongue swelling in association with oseltamivir (Tamiflu). British Medical Journal Case Reports 2011; 2011. pii: bcr0620114396. doi:10.1136/ bcr.06.2011.4396
83. Smith EV, Pynn MC, Blackford S, Leopold DJ. Stevens-Johnson syndrome secondary to oseltamivir (Tamiflu). British Journal of General Practice 2010; 60(571): 133-134. doi:10.3399/ bjgp10X483292
84. Zuo W, Wen LP, Li J, Mei D, Fu Q, Zhang B. Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report. Medicine (Baltimore) 2019; 98 (19): e15553. doi:10.1097/ MD.0000000000015553
85. Luna P, Zuazaga M, Chede C, Entin E, Larralde M. Toxic epidermal necrolysis after treatment with oseltamivir: case report. Archivos Argentinos de Pediatria 2010; 108 (3): e76-8. doi:10.1590/S0325- 00752010000300013
86. Calista D. Maculo-papular rash induced by lopinavir/ritonavir. European Journal of Dermatology 2005; 15 (2): 97-98.
87. Ghosn J, Duvivier C, Tubiana R, Katlama C, Caumes E. Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir. Clinical Infectious Diseases 2005; 41 (9): 1360-1361.
88. Cao B, Wang Y, Wen D, Liu W, Wang J et al. Trial of lopinavirritonavir in adults hospitalized with severe COVID-19. New England Journal of Medicine 2020; 382 (19): 1787-1799. doi:10.1056/NEJMoa2001282